Fractyl Health (NASDAQ:GUTS) Upgraded at Craig Hallum

Fractyl Health (NASDAQ:GUTS) was upgraded by investment analysts at Craig Hallum to a “strong-buy” rating in a research report issued on Wednesday,Zacks.com reports.

GUTS has been the subject of several other research reports. Canaccord Genuity Group restated a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a report on Thursday, March 26th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Fractyl Health in a report on Tuesday, May 12th. Wall Street Zen upgraded shares of Fractyl Health from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of Fractyl Health in a research note on Thursday, June 4th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.12.

Fractyl Health Trading Down 0.9%

NASDAQ GUTS opened at $0.79 on Wednesday. Fractyl Health has a 52 week low of $0.38 and a 52 week high of $2.44. The firm has a 50 day moving average of $0.78 and a two-hundred day moving average of $0.97. The company has a quick ratio of 4.28, a current ratio of 4.28 and a debt-to-equity ratio of 1.41. The stock has a market capitalization of $124.86 million, a PE ratio of -0.61 and a beta of 2.29.

Fractyl Health (NASDAQ:GUTS) last announced its quarterly earnings data on Tuesday, May 12th. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.23. As a group, research analysts expect that Fractyl Health will post -0.6 EPS for the current fiscal year.

Insiders Place Their Bets

In other Fractyl Health news, Director William Bradley acquired 68,493 shares of the company’s stock in a transaction that occurred on Wednesday, June 10th. The shares were purchased at an average price of $0.73 per share, with a total value of $49,999.89. Following the completion of the acquisition, the director directly owned 84,622 shares of the company’s stock, valued at approximately $61,774.06. The trade was a 424.66% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Ian Sheffield purchased 35,000 shares of the stock in a transaction dated Wednesday, June 10th. The shares were bought at an average cost of $0.73 per share, for a total transaction of $25,550.00. Following the completion of the purchase, the director owned 35,000 shares in the company, valued at approximately $25,550. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 171,493 shares of company stock worth $127,150 in the last ninety days. 8.52% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Fractyl Health

Several institutional investors and hedge funds have recently made changes to their positions in GUTS. Woodline Partners LP grew its stake in Fractyl Health by 47.2% in the 1st quarter. Woodline Partners LP now owns 516,921 shares of the company’s stock valued at $615,000 after acquiring an additional 165,786 shares during the last quarter. Qube Research & Technologies Ltd acquired a new position in Fractyl Health during the second quarter worth about $129,000. General Catalyst Group Management LLC purchased a new stake in shares of Fractyl Health in the second quarter valued at about $7,912,000. Jane Street Group LLC purchased a new stake in shares of Fractyl Health in the second quarter valued at about $31,000. Finally, Osaic Holdings Inc. grew its position in shares of Fractyl Health by 460.3% in the second quarter. Osaic Holdings Inc. now owns 59,645 shares of the company’s stock valued at $97,000 after purchasing an additional 49,000 shares during the last quarter.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.